NCT02671266 - Oxytocin Administration in BDD and OCD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions

Body Dysmorphic DisorderObsessive-compulsive Disorder

Interventions

DRUG

Oxytocin

Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.

DRUG

Placebo

Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.

Trial Locations (1)

02114

Massachusetts General Hospital/Harvard Medical School, Boston

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER